evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,234 questions · 2,325 findings · 216 reviews · Airways

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 249 · 10.7%GRADE not reported 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%

Mepolizumab 100 mg vs placebo

Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations All participants compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 10 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 10 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 10 mg vs placebo

Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg probably leads to lower rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 30 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 30 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 30 mg vs placebo

Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (moderate certainty).

1 finding from 1 review

Mepolizumab 100 mg vs placebo

Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (high certainty).

1 finding from 1 review

Benralizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils ≥ 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 100 mg vs placebo

Rate of moderate or severe exacerbations Eosinophils < 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophils < 220/μL compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab 100 mg vs placebo

Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg leads to lower rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (high certainty).

1 finding from 1 review